Cargando…
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC). METHODS: A panel of expert on...
Autores principales: | Reck, M., Barlesi, F., Crinò, L., Henschke, C. I., Isla, D., Stiebeler, S., Spigel, D. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335247/ https://www.ncbi.nlm.nih.gov/pubmed/22056855 http://dx.doi.org/10.1093/annonc/mdr463 |
Ejemplares similares
-
Hyperkalemia management in the emergency department: An expert panel consensus
por: Rafique, Zubaid, et al.
Publicado: (2021) -
A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study
por: Isla, Dolores, et al.
Publicado: (2022) -
Critical Resources for Hospital Surge Capacity: An Expert Consensus Panel
por: Bayram, Jamil D., et al.
Publicado: (2013) -
International Expert Panel Consensus on Fat Grafting of the Breast
por: Nava, Maurizio B., et al.
Publicado: (2019) -
An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertension
por: Wilson, Melisa, et al.
Publicado: (2022)